WO1999008684A3 - Solutions containing azasteroids - Google Patents

Solutions containing azasteroids Download PDF

Info

Publication number
WO1999008684A3
WO1999008684A3 PCT/EP1998/005192 EP9805192W WO9908684A3 WO 1999008684 A3 WO1999008684 A3 WO 1999008684A3 EP 9805192 W EP9805192 W EP 9805192W WO 9908684 A3 WO9908684 A3 WO 9908684A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
discloses
azasteroids
solutions containing
another aspect
Prior art date
Application number
PCT/EP1998/005192
Other languages
French (fr)
Other versions
WO1999008684A2 (en
Inventor
Alan Frank Parr
Michele Catherine Rizzolio
Original Assignee
Glaxo Group Ltd
Alan Frank Parr
Michele Catherine Rizzolio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Alan Frank Parr, Michele Catherine Rizzolio filed Critical Glaxo Group Ltd
Priority to JP51280799A priority Critical patent/JP2002511100A/en
Priority to AU89796/98A priority patent/AU8979698A/en
Priority to KR19997012115A priority patent/KR20010014079A/en
Priority to EP98941422A priority patent/EP1005346A2/en
Priority to CA002295023A priority patent/CA2295023A1/en
Priority to BR9810285-0A priority patent/BR9810285A/en
Publication of WO1999008684A2 publication Critical patent/WO1999008684A2/en
Publication of WO1999008684A3 publication Critical patent/WO1999008684A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Abstract

The present invention discloses a novel solution comprising a therapeutically effective amount of a pharmaceutically active aza steroid, polyethylene glycol, and propylene glycol. In another aspect, the present invention discloses a pharmaceutical composition comprising the solution of the invention. In another aspect, the present invention discloses a gelatin capsule filled with the composition of the present invention.
PCT/EP1998/005192 1997-08-19 1998-08-17 Solutions containing azasteroids WO1999008684A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP51280799A JP2002511100A (en) 1997-08-19 1998-08-17 Solutions containing azasteroids
AU89796/98A AU8979698A (en) 1997-08-19 1998-08-17 Solutions containing azasteroids
KR19997012115A KR20010014079A (en) 1997-08-19 1998-08-17 Solutions containing azasteroids
EP98941422A EP1005346A2 (en) 1997-08-19 1998-08-17 Solutions containing azasteroids
CA002295023A CA2295023A1 (en) 1997-08-19 1998-08-17 Solutions containing azasteroids
BR9810285-0A BR9810285A (en) 1997-08-19 1998-08-17 Solution, pharmaceutical composition, and gelatin capsule.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9717444.5A GB9717444D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition
GB9717444.5 1997-08-19

Publications (2)

Publication Number Publication Date
WO1999008684A2 WO1999008684A2 (en) 1999-02-25
WO1999008684A3 true WO1999008684A3 (en) 1999-06-10

Family

ID=10817633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/005192 WO1999008684A2 (en) 1997-08-19 1998-08-17 Solutions containing azasteroids

Country Status (10)

Country Link
EP (1) EP1005346A2 (en)
JP (1) JP2002511100A (en)
KR (1) KR20010014079A (en)
CN (1) CN1263466A (en)
AU (1) AU8979698A (en)
BR (1) BR9810285A (en)
CA (1) CA2295023A1 (en)
GB (1) GB9717444D0 (en)
TR (1) TR199903211T2 (en)
WO (1) WO1999008684A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (en) * 2002-11-22 2004-05-23 Omega Farma Ehf. Compositions of finasteride tablets
CZ300438B6 (en) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Process for preparing solid medicament form for oral administration with instantaneous release of active substance and containing as the active substance finasteride polymorphous form
EP1704162A1 (en) * 2004-01-02 2006-09-27 PharmaCon Forschung und Beratung GmbH Method for producing 1,2-unsaturated azasteroids
EP2050436A1 (en) 2007-12-21 2009-04-22 Siegfried Generics International AG Pharmaceutical composition containing dutasteride
DE102008059201A1 (en) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ precipitating drug solutions
KR101055412B1 (en) * 2010-11-19 2011-08-08 (주)비씨월드제약 Composition for self-emulsifying preparation comprising dutasteride and manufacturing process thereof
CN103169712B (en) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 Improve dutasteride's preparation of bioavilability and preparation method thereof
NZ724002A (en) * 2012-05-18 2017-07-28 Luoda Pharma Pty Ltd Liquid formulation comprising propylene glycol and an ace inhibitor
CN103479595B (en) * 2012-06-13 2015-08-26 成都国弘医药有限公司 A kind of soft capsule containing dutasteride
WO2014002015A1 (en) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition comprising dutasteride
CN103830201A (en) * 2012-11-20 2014-06-04 重庆医药工业研究院有限责任公司 Dutasteride liquid soft capsules
ES2555485T1 (en) 2014-05-26 2016-01-04 Galenicum Health S.L. Pharmaceutical compositions containing an active agent
JP7017938B2 (en) * 2018-01-15 2022-02-09 森下仁丹株式会社 3-oxo-4-azaandrost-1-ene-17-carboxylic acid derivative-containing preparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000010A1 (en) * 1990-06-27 1992-01-09 Smithkline Beecham Corporation Method of treating human prostatic adenocarcinoma
WO1995007926A1 (en) * 1993-09-17 1995-03-23 Glaxo Wellcome Inc. Androstenones
US5516768A (en) * 1990-03-16 1996-05-14 Smithkline Beecham Corporation Uncompetitive inhibition of steroid and 5α-reductose
WO1997011702A1 (en) * 1995-09-27 1997-04-03 Merck & Co., Inc. Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors
WO1998025463A1 (en) * 1996-12-09 1998-06-18 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516768A (en) * 1990-03-16 1996-05-14 Smithkline Beecham Corporation Uncompetitive inhibition of steroid and 5α-reductose
WO1992000010A1 (en) * 1990-06-27 1992-01-09 Smithkline Beecham Corporation Method of treating human prostatic adenocarcinoma
WO1995007926A1 (en) * 1993-09-17 1995-03-23 Glaxo Wellcome Inc. Androstenones
WO1997011702A1 (en) * 1995-09-27 1997-04-03 Merck & Co., Inc. Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors
WO1998025463A1 (en) * 1996-12-09 1998-06-18 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss

Also Published As

Publication number Publication date
AU8979698A (en) 1999-03-08
CN1263466A (en) 2000-08-16
WO1999008684A2 (en) 1999-02-25
KR20010014079A (en) 2001-02-26
JP2002511100A (en) 2002-04-09
TR199903211T2 (en) 2000-04-21
GB9717444D0 (en) 1997-10-22
CA2295023A1 (en) 1999-02-25
EP1005346A2 (en) 2000-06-07
BR9810285A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
ES8503508A1 (en) Pharmaceutical compositions.
ZA964873B (en) Tricot-like pouch for the delivery of topical drugs and cosmetics.
NZ280610A (en) Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
WO2001041737A3 (en) Solid oral dosage form
HUP9900028A3 (en) Pharmaceutically active quinazoline compounds, their production, use thereof and medicament containing them
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
HK1034897A1 (en) A double capsule for the administration of active principles in multiple therapies.
CA2326485A1 (en) Anticancer compositions
WO1995017156A3 (en) Ethanol substitutes
HU0301171D0 (en) Antifungal active ingredients, pharmaceutical compositions containing the same and process for their preparation
WO1999008684A3 (en) Solutions containing azasteroids
CA2172616A1 (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
AU7595498A (en) Medicament dispensing cell
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
EP0645136A3 (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation.
IL117706A0 (en) Powdered drug storage and delivery system
PL313113A1 (en) Novel pharmaceutical agent for oral administration containing progesterone and polyethylene glycol
AU2619997A (en) Fill material for soft gelatin pharmaceutical dosage form
AU3053199A (en) Fused thiophene derivatives and drugs containing the same as the active ingredient
ZA968715B (en) Stable pharmaceutical forms of administration containing parathyroid hormone.
HUP9700005A3 (en) 2-ureido-benzamide derivatives and pharmaceutical compositions containing them as active agent
ZA200007415B (en) Amino acid derivatives and drugs containing the same as the active ingredient.
AU1671799A (en) Medicament preparation in the form of a tablet or pellet for acid-labile active substances
WO1999008666A3 (en) Pharmaceutical composition comprising an azateroid

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98806379.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/011995

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2295023

Country of ref document: CA

Ref document number: 2295023

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 89796/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998941422

Country of ref document: EP

Ref document number: 1019997012115

Country of ref document: KR

Ref document number: 1999/03211

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 09485550

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998941422

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997012115

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998941422

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997012115

Country of ref document: KR